DexTech's Phase IIb study for OsteoDex concludes with positive follow-up results
The company's Phase IIb study for the treatment of skeletal metastatic castration-resistant prostate cancer (mCRPC) shows continued promising follow-up data and confirms previously announced partial results.Formalities in the form of closing the study database (database base lock) and signing of follow-up forms (eCRFs) have been delayed somewhat as a result of the ongoing virus pandemic. The study's final results, including 2-year survival data, will be presented, together with the company's and CEO's comments, in the form of a press release in June. For additional information: